Trevena Inc (NASDAQ:TRVN) Can’t Be More Risky. Short Interest Increased

October 13, 2018 - By Ellis Scott

Trevena, Inc. (NASDAQ:TRVN) Logo

The stock of Trevena Inc (NASDAQ:TRVN) registered an increase of 0.22% in short interest. TRVN’s total short interest was 5.95 million shares in October as published by FINRA. Its up 0.22% from 5.94M shares, reported previously. With 1.10 million shares average volume, it will take short sellers 5 days to cover their TRVN’s short positions.

The stock decreased 7.06% or $0.0669 during the last trading session, reaching $0.8801. About 12.36 million shares traded or 262.77% up from the average. Trevena, Inc. (NASDAQ:TRVN) has declined 40.14% since October 13, 2017 and is downtrending. It has underperformed by 55.76% the S&P500.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has market cap of $66.96 million. The Company’s product candidates include oliceridine injection, a ??-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. It currently has negative earnings.

Trevena, Inc. (NASDAQ:TRVN) Ratings Coverage

Among 2 analysts covering Trevena (NASDAQ:TRVN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Trevena had 2 analyst reports since October 10, 2018 according to SRatingsIntel. As per Friday, October 12, the company rating was maintained by H.C. Wainwright. The stock of Trevena, Inc. (NASDAQ:TRVN) earned “Hold” rating by Jefferies on Wednesday, October 10.

More notable recent Trevena, Inc. (NASDAQ:TRVN) news were published by: Seekingalpha.com which released: “Trevena adds to rally, up 15%” on October 03, 2018, also Benzinga.com with their article: “Trevena Shares Plunge As FDA Briefing Document Reveals Pain Drug Concerns” published on October 09, 2018, Seekingalpha.com published: “Trevena down 13% premarket after negative Ad Com vote” on October 12, 2018. More interesting news about Trevena, Inc. (NASDAQ:TRVN) were released by: Seekingalpha.com and their article: “Trevena discloses change of Phase 3 endpoints for oliceridine after FDA discussions” published on October 11, 2018 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 10/12: (CORI) (TTPH) (SQ) Higher; (IMDZ) (TRVN) Lower (more…)” with publication date: October 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>